1. Proteostasis Therapeutics, Inc. (20 from 24 patents)

2. The Broad Institute, Inc. (16 from 443 patents)

3. Merck + Co., Inc. (9 from 4,770 patents)

4. Merck Sharp + Dohme Corp. (5 from 2,405 patents)

5. Dana-farber-cancer Institute Inc. (5 from 1,209 patents)

6. Massachusetts Institute of Technology (4 from 8,373 patents)

7. The General Hospital Corporation (4 from 2,893 patents)

8. Harvard College (3 from 2,963 patents)

9. Other (2 from 832,843 patents)

10. Whitehead Institute for Biomedical Research (2 from 303 patents)

11. Kineta, Inc. (2 from 14 patents)

12. Bristol-myers Squibb Compnay (1 from 3,684 patents)

13. The Brigham and Women's Hospital, Inc. (1 from 1,373 patents)

14. Beth Israel Deaconess Medical Center, Inc. (1 from 517 patents)

15. Massachusetts General Hospital Corporation (1 from 83 patents)

1. 12419885 - Kinase inhibitors and methods of use thereof

2. 12319698 - Proteasome activity enhancing compounds

3. 11958873 - Proteasome activity enhancing compounds

4. 11560385 - Proteasome activity enhancing compounds

5. 11325913 - Compounds and methods for the treatment of malaria

6. 11248010 - Compounds, compositions, and methods for modulating CFTR

7. 11242361 - Proteasome activity enhancing compounds

8. 11136313 - Compounds, compositions, and methods for modulating CFTR

9. 11098035 - Compounds, compositions, and methods for increasing CFTR activity

10. 11083709 - Compounds, compositions, and methods of increasing CFTR activity

11. 11052080 - Kinase inhibitors and methods of use thereof

12. 10899751 - Compounds, compositions, and methods for increasing CFTR activity

13. 10738055 - Compounds and methods for the treatment of malaria

14. 10738040 - Compounds, compositions, and methods for increasing CFTR activity

15. 10738011 - Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis